Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vidofludimus calcium - Immunic

Next Previous
Drug Profile

Vidofludimus calcium - Immunic

Alternative Names: 4SC-101; IM 90838; IMU 838; SC-12267; VidoCa

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC
  • Developer 4SC; Arizona State University; Immunic; Mayo Clinic
  • Class Amides; Anti-inflammatories; Antivirals; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Nuclear receptor subfamily 4 group A member 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II/III COVID 2019 infections
  • Phase II Crohn's disease; Ulcerative colitis
  • Discontinued Inflammatory bowel diseases; Primary sclerosing cholangitis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 20 Mar 2024 Immunic has patents pending for Vidofludimus calcium and other salt forms as well as free acid forms for treating neurodegenerative diseases in the US
  • 20 Mar 2024 The US Patent and Trademark Office issues a Notice of Allowance for patent application for Vidofludimus calcium in USA
  • 29 Feb 2024 Efficacy data from a phase II CALLIPER trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top